公开(公告)号：US09200058B2

公开(公告)日：2015-12-01

申请号：US13635874

申请日：2011-03-18

Applicant: Young Woo Park ,  Ki Won Jo ,  Srok Ho Yoo ,  Jung Yu ,  Sun-Ha Yoon ,  Ji Hyun Park ,  Eun Jung Song ,  Jong-Ho Lee ,  Min Ji Seo ,  Sun Jung Cho ,  Mi La Cho ,  Ho Youn Kim ,  Mi Kyung Park ,  Hye Jwa Oh ,  Jin Sil Park ,  Yun Ju Woo ,  Jae Kyeong Byun ,  Jun Geol Ryu

Inventor： Young Woo Park ,  Ki Won Jo ,  Srok Ho Yoo ,  Jung Yu ,  Sun-Ha Yoon ,  Ji Hyun Park ,  Eun Jung Song ,  Jong-Ho Lee ,  Min Ji Seo ,  Sun Jung Cho ,  Mi La Cho ,  Ho Youn Kim ,  Mi Kyung Park ,  Hye Jwa Oh ,  Jin Sil Park ,  Yun Ju Woo ,  Jae Kyeong Byun ,  Jun Geol Ryu

IPC: C07K14/715

CPC classification number: C07K14/7151 ,  C07K14/7155 ,  C07K2319/00

Abstract: The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (α) and IL-21. The composition containing the double antagonist to TNF-α and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.

Abstract translation: 本发明涉及作为TNF-α（α）和IL-21的双重拮抗剂的TNFR2-IL21R融合蛋白。 含有TNF-α和II-21（TNFR2-IL21R融合蛋白）的双重拮抗剂的组合物，被称为自身免疫性类风湿性关节炎的主要原因（自身免疫性疾病之一）可以减少炎性细胞因子的分泌， 炎性细胞因子，并且比单一蛋白如TNFR2-Fc和IL21R-Fc更好地抑制破骨细胞的分化。 本发明的TNFR2-IL21R融合蛋白不仅对CIA小鼠模型的关节炎具有优异的治疗作用，而且通过增加免疫抑制细胞Treg的表达，对自身免疫性类风湿性关节炎也不是很好的治疗效果。 因此，本发明的TNFR2-IL21R融合蛋白可以有效地用作预防和治疗自身免疫性疾病的组合物的活性成分。

公开(公告)号：US20130022642A1

公开(公告)日：2013-01-24

申请号：US13635874

申请日：2011-03-18

Applicant: Young Woo Park ,  Ki Won Jo ,  Srok Ho Yoo ,  Jung Yu ,  Sun-Ha Yoon ,  Ji Hyun Park ,  Eun Jung Song ,  Jong-Ho Lee ,  Min Ji Seo ,  Sun Jung Cho ,  Mi La Cho ,  Ho Youn Kim ,  Mi Kyung Park ,  Hye Jwa Oh ,  Jin Sil Park ,  Yun Ju Woo ,  Jae Kyeong Byun ,  Jun Geol Ryu

Inventor： Young Woo Park ,  Ki Won Jo ,  Srok Ho Yoo ,  Jung Yu ,  Sun-Ha Yoon ,  Ji Hyun Park ,  Eun Jung Song ,  Jong-Ho Lee ,  Min Ji Seo ,  Sun Jung Cho ,  Mi La Cho ,  Ho Youn Kim ,  Mi Kyung Park ,  Hye Jwa Oh ,  Jin Sil Park ,  Yun Ju Woo ,  Jae Kyeong Byun ,  Jun Geol Ryu

IPC: C07K19/00 ,  C12N15/63 ,  C12N1/21 ,  C12N5/10 ,  A61K38/17 ,  A61P21/00 ,  A61P3/10 ,  A61P19/02 ,  A61P37/06 ,  A61P25/00 ,  A61P17/00 ,  C12N15/62 ,  A61P7/06

CPC classification number: C07K14/7151 ,  C07K14/7155 ,  C07K2319/00

Abstract: The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (α) and IL-21. The composition containing the double antagonist to TNF-α and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.

Abstract translation: 本发明涉及作为TNF-α（α）和IL-21的双重拮抗剂的TNFR2-IL21R融合蛋白。 含有TNF-α和II-21（TNFR2-IL21R融合蛋白）的双重拮抗剂的组合物，被称为自身免疫性类风湿性关节炎的主要原因（自身免疫性疾病之一）可以减少炎性细胞因子的分泌， 炎性细胞因子，并且比单一蛋白如TNFR2-Fc和IL21R-Fc更好地抑制破骨细胞的分化。 本发明的TNFR2-IL21R融合蛋白不仅对CIA小鼠模型的关节炎具有优异的治疗作用，而且通过增加免疫抑制细胞Treg的表达，对自身免疫性类风湿性关节炎也不是很好的治疗效果。 因此，本发明的TNFR2-IL21R融合蛋白可以有效地用作预防和治疗自身免疫性疾病的组合物的活性成分。

公开(公告)号：US08486905B2

公开(公告)日：2013-07-16

申请号：US12746722

申请日：2008-12-05

Applicant: Misun Won ,  Kyung-Sook Chung ,  Young-Joo Kim ,  Shin-Jung Choi ,  Young Il Yeom ,  Seon-Young Kim ,  Kyung Bin Song ,  Hee Gu Lee ,  Eun Young Song ,  Young Ho Kim ,  Ho Kyung Chun ,  Chae-Ok Yun ,  Moon Hee Kim ,  Kyeong-Eun Jung ,  Sun-Jung Cho

Inventor： Misun Won ,  Kyung-Sook Chung ,  Young-Joo Kim ,  Shin-Jung Choi ,  Young Il Yeom ,  Seon-Young Kim ,  Kyung Bin Song ,  Hee Gu Lee ,  Eun Young Song ,  Young Ho Kim ,  Ho Kyung Chun ,  Chae-Ok Yun ,  Moon Hee Kim ,  Kyeong-Eun Jung ,  Sun-Jung Cho

IPC: C12N15/11 ,  C07H21/02

CPC classification number: G01N33/57484 ,  A61K31/7088 ,  A61K38/1709 ,  C12N15/1135 ,  C12N15/86 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2710/10343 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2500/00 ,  G01N2500/04

Abstract: Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.

Abstract translation: 提供了用于诊断癌症或筛选包含FLJ25416基因或针对从FLJ25416基因表达的蛋白质的抗体的抗癌药物的组合物，用于治疗癌症的组合物，其包含该基因的抑制剂或从该基因表达的蛋白质的抑制剂 和药学上可接受的载体，以及用于诊断癌症的试剂盒，其包含FLJ25416基因和从FLJ25416基因表达的蛋白质中的至少一种。 FLJ25416基因在特异性癌细胞中表达量高，诱导正常细胞增殖。 该基因的表达被抑制，这导致对癌细胞生长的抑制作用。 因此，FLJ25416基因可用作癌症诊断或治疗的靶基因。

公开(公告)号：US20110008370A1

公开(公告)日：2011-01-13

申请号：US12746722

申请日：2008-12-05

Applicant: Misun Won ,  Kyung-Sook Chung ,  Young-Joo Kim ,  Shin-Jung Choi ,  Young Il Yeom ,  Seon-Young Kim ,  Kyung Bin Song ,  Hee Gu Lee ,  Eun Young Song ,  Young Ho Kim ,  Ho Kyung Chun ,  Chae-Ok Yun ,  Moon Hee Kim ,  Kyeong-Eun Jung ,  Sun-Jung Cho

Inventor： Misun Won ,  Kyung-Sook Chung ,  Young-Joo Kim ,  Shin-Jung Choi ,  Young Il Yeom ,  Seon-Young Kim ,  Kyung Bin Song ,  Hee Gu Lee ,  Eun Young Song ,  Young Ho Kim ,  Ho Kyung Chun ,  Chae-Ok Yun ,  Moon Hee Kim ,  Kyeong-Eun Jung ,  Sun-Jung Cho

IPC: A61K39/395 ,  C07H21/02 ,  A61K31/713 ,  C07H21/00 ,  C07K16/18 ,  C07K14/47 ,  C12Q1/68 ,  G01N33/574 ,  A61P35/00

CPC classification number: G01N33/57484 ,  A61K31/7088 ,  A61K38/1709 ,  C12N15/1135 ,  C12N15/86 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2710/10343 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2500/00 ,  G01N2500/04

Abstract: Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.

Abstract translation: 提供了用于诊断癌症或筛选包含FLJ25416基因或针对由FLJ25416基因表达的蛋白质的抗体的抗癌药物的组合物，用于治疗癌症的组合物，其包含该基因的抑制剂或从该基因表达的蛋白质的抑制剂 和药学上可接受的载体，以及用于诊断癌症的试剂盒，其包含FLJ25416基因和从FLJ25416基因表达的蛋白质中的至少一种。 FLJ25416基因在特异性癌细胞中表达量高，诱导正常细胞增殖。 该基因的表达被抑制，这导致对癌细胞生长的抑制作用。 因此，FLJ25416基因可用作癌症诊断或治疗的靶基因。